Inovio doses first patient in phase 2 segment of Covid-19 DNA vaccine candidate trial

Inovio Pharmaceuticals has dosed its first subject in phase 2 segment of its INNOVATE Phase 2/3 Clinical Trial for Covid-19 DNA vaccine candidate. The phase 2 segment has been designed to assess the safety and immunogenicity of INO-4800 Covid-19 vaccine candidate to confirm the dose for the subsequent efficacy assessment as part of the phase 3 segment of the trial.